Rapid Improvement in Weight, Body Composition, and Glucose Variability With Semaglutide in Type 1 Diabetes.

Gad H, Malik RA

Cureus3 Jun 2024Cited by 2 (Europe PMC)

PMID38962634PMCIDPMC11221340DOI10.7759/cureus.61577PepBankPUB-38962634

Summary

The efficacy of glucagon-like peptide-1 receptor agonists (GLP1-RA) in type 2 diabetes mellitus is well-established. GLP1-RAs are not approved for use in type 1 diabetes mellitus (T1DM). A 34-year-old woman with a 23-year history of T1DM presented for review for weight gain (weight 63 kg, BMI 26.9 kg/m²) and increased HbA1c (8.3%) and glycemic variability. Subcutaneous semaglutide (1 mg weekly) was commenced. After two months, there was decrease in weight by 12 kg, body fat percent by 15%, visceral fat by 7%, and a reduction in insulin dose, glycemic variability, and HbA1c. Semaglutide could be an important adjunct to insulin treatment in T1DM.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanCase report or seriesEfficacy outcome
In a woman with type 1 diabetes, weight fell by 12 kg after two months of semaglutide.
In plain wordsIn one woman with type 1 diabetes, weight fell by 12 kg after two months of semaglutide.
Peptide
Semaglutide
Outcome
DecreaseBody weight change
Study
n = 1
Outcome group
Body weight · Metabolic and weight
Studied dose
1 mg weekly · subcutaneous · 2 monthsAs given in this study (human).
Measurements
Weight change
−12 kg
after 2 months
Source sentences
Summary
After two months, there was decrease in weight by 12 kg
1 context sentence(design, population, supporting numbers)
Summary · context
A 34-year-old woman with a 23-year history of T1DM presented for review for weight gain (weight 63 kg, BMI 26.9 kg/m²) and increased HbA1c (8.3%) and glycemic variability.
Show in the study text Report a problemFND-3896263401
02HumanCase report or seriesEfficacy outcome
In a woman with type 1 diabetes, body fat percentage fell by 15% after two months of semaglutide.
In plain wordsIn one woman with type 1 diabetes, body fat fell by 15% after two months of semaglutide.
Peptide
Semaglutide
Outcome
DecreaseBody fat percentage change
Study
n = 1
Outcome group
Body weight · Metabolic and weight
Studied dose
1 mg weekly · subcutaneous · 2 monthsAs given in this study (human).
Measurements
Body fat change
−15%
after 2 months
Source sentences
Summary
After two months, there was decrease in weight by 12 kg, body fat percent by 15%
1 context sentence(design, population, supporting numbers)
Summary · context
A 34-year-old woman with a 23-year history of T1DM presented for review for weight gain (weight 63 kg, BMI 26.9 kg/m²) and increased HbA1c (8.3%) and glycemic variability.
Show in the study text Report a problemFND-3896263402
03HumanCase report or seriesEfficacy outcome
In a woman with type 1 diabetes, visceral fat fell by 7% after two months of semaglutide.
In plain wordsIn one woman with type 1 diabetes, belly fat around the organs fell by 7% after two months of semaglutide.
Peptide
Semaglutide
Outcome
DecreaseVisceral fat change
Study
n = 1
Outcome group
Body weight · Metabolic and weight
Studied dose
1 mg weekly · subcutaneous · 2 monthsAs given in this study (human).
Measurements
Visceral fat change
−7%
after 2 months
Source sentences
Summary
After two months, there was decrease in weight by 12 kg, body fat percent by 15%, visceral fat by 7%
1 context sentence(design, population, supporting numbers)
Summary · context
A 34-year-old woman with a 23-year history of T1DM presented for review for weight gain (weight 63 kg, BMI 26.9 kg/m²) and increased HbA1c (8.3%) and glycemic variability.
Show in the study text Report a problemFND-3896263403
04HumanCase report or seriesEfficacy outcome
In a woman with type 1 diabetes, the insulin dose was reduced after two months of semaglutide.
In plain wordsIn one woman with type 1 diabetes, her insulin dose could be reduced after two months of semaglutide.
Peptide
Semaglutide
Outcome
DecreaseInsulin dose
Study
n = 1
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1 mg weekly · subcutaneous · 2 monthsAs given in this study (human).
Source sentences
Summary
After two months, there was decrease in weight by 12 kg, body fat percent by 15%, visceral fat by 7%, and a reduction in insulin dose
1 context sentence(design, population, supporting numbers)
Summary · context
A 34-year-old woman with a 23-year history of T1DM presented for review for weight gain (weight 63 kg, BMI 26.9 kg/m²) and increased HbA1c (8.3%) and glycemic variability.
Show in the study text Report a problemFND-3896263404
05HumanCase report or seriesEfficacy outcome
In a woman with type 1 diabetes, glycemic variability fell after two months of semaglutide.
In plain wordsIn one woman with type 1 diabetes, blood sugar swings became smaller after two months of semaglutide.
Peptide
Semaglutide
Outcome
DecreaseGlycemic variability
Study
n = 1
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1 mg weekly · subcutaneous · 2 monthsAs given in this study (human).
Source sentences
Summary
After two months, there was decrease in weight by 12 kg, body fat percent by 15%, visceral fat by 7%, and a reduction in insulin dose, glycemic variability
1 context sentence(design, population, supporting numbers)
Summary · context
A 34-year-old woman with a 23-year history of T1DM presented for review for weight gain (weight 63 kg, BMI 26.9 kg/m²) and increased HbA1c (8.3%) and glycemic variability.
Show in the study text Report a problemFND-3896263405
06HumanCase report or seriesEfficacy outcome
In a woman with type 1 diabetes, HbA1c fell after two months of semaglutide.
In plain wordsIn one woman with type 1 diabetes, her average blood sugar marker HbA1c fell after two months of semaglutide.
Peptide
Semaglutide
Outcome
DecreaseHbA1c
Study
n = 1
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1 mg weekly · subcutaneous · 2 monthsAs given in this study (human).
Source sentences
Summary
After two months, there was decrease in weight by 12 kg, body fat percent by 15%, visceral fat by 7%, and a reduction in insulin dose, glycemic variability, and HbA1c.
1 context sentence(design, population, supporting numbers)
Summary · context
A 34-year-old woman with a 23-year history of T1DM presented for review for weight gain (weight 63 kg, BMI 26.9 kg/m²) and increased HbA1c (8.3%) and glycemic variability.
Show in the study text Report a problemFND-3896263406

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.